
(POLYX)
Polymesh (POLYX) price prediction for 2026-2030Listed
How has Polymesh (POLYX) performed this year? What are the short-term outlooks (1 week, 1 month, 3 months) and the long-term forecast for 2026-2030? We analyze and forecast POLYX's future price based on recent trends, historical data, and technical indicators such as Moving Averages (MA), RSI, and MACD. You can also use our price prediction tool to estimate potential returns by setting your target growth rate.
Polymesh (POLYX) price
Last updated: Aug 19, 2026, 17:49:44
24h high
0.028750 USD
Market cap
38.63M USD
24h low
0.027630 USD
24h volume
632.47K USD
Polymesh (POLYX) price
0.0295 USD
Date
--
Enter your expected growth for Polymesh to calculate its future value
Current price
0.0295 USD
Momentum
Bearish
14D RSI
86.42
50D EMA
0.033986 USD
200W SMA
0.042869 USD
Fear & Greed
44
1. Weekly EMA 200
The weekly EMA 200 is a widely used bull/bear market divider and long-term trend line in crypto.
2. Daily EMA 50
3. MACD trend & reversal signals
Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.
Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.